Share Name Share Symbol Market Type Share ISIN Share Description
Scientific D. LSE:SDI London Ordinary Share GB00B3FBWW43 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 40.50p 39.00p 42.00p 40.50p 40.50p 40.50p 1,342,000 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 10.7 0.9 0.0 - 35.98

Scientific Digital Imaging Share Discussion Threads

Showing 1176 to 1199 of 1200 messages
Chat Pages: 48  47  46  45  44  43  42  41  40  39  38  37  Older
DateSubjectAuthorDiscuss
24/5/2018
13:51
Tudes100 we had a TU last month, so not expecting anything further until the prelims. Unless of course another acquisition is completed, which isn't beyond the realms of possibility.
hastings
24/5/2018
13:07
Trading update LY on May 26th, I wonder ?!
tudes100
24/5/2018
10:21
That's a rather nice £133,000 buy at 41.25p just reported.
rivaldo
10/5/2018
15:40
Could I please ask for the SDI BOD bring forwards the full year results this time round ie ASAP , within the next 10 days
buywell3
08/5/2018
12:35
Further to hasting's post above, here's SDI's own take on the new product launch: Https://www.synbiosis.com/news/protocol-3-hd-colony-counter-launch/
rivaldo
04/5/2018
12:10
https://www.cambridgenetwork.co.uk/news/new-synbiosis-protocol-3-hd-colony-count-and-zone-measuremen1306/
hastings
04/5/2018
08:17
Yes, looks good. On acquisitions I'd personally be surprised if we don't have another in the next six moths!
hastings
04/5/2018
08:11
Ametek, Inc. where his principle duties include performance management, M&A, business controls and accounting for several scientific and industrial instrument businesses. Reading his recent areas of responsibility it would seem that he is the perfect appointment for SDI, wouldn't be a surprise to see another acquisition this year.
interceptor2
04/5/2018
07:45
Great minds think alike hastings :o))
rivaldo
04/5/2018
07:15
Good to see a new CFO with a decent background appointed, which is welcome given the now enlarged and increasing scale of the business.
hastings
04/5/2018
07:15
Very impressive, heavyweight CFO appointment today, indicating SDI's ambition and transformation: Https://www.investegate.co.uk/scientific-dig-imag--sdi-/rns/directorate-appointment/201805040700090686N/
rivaldo
02/5/2018
13:01
Cheers rivaldo good to see. Syngene has been transformed over the last 18 months and now has some really clever and sparky young people driving new products and sales.For so long a mundane business that lacked growth it's now securing new business in a wide range of territories and importantly is profitable.Now an important component of the group.
hastings
02/5/2018
12:30
News - a new product range: Https://www.syngene.com/news/sleek-new-blue-gbox-multi-application-imaging-range-syngene/ "Sleek, new blue G:BOX multi-application imaging range from Syngene May 1st, 2018 Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to introduce its new look G:BOX range of upgradeable multi-application imaging systems. Designed with a sleek new darkroom, each of these systems includes top quality imaging features, making it easy for scientists to accurately quantify DNA and protein on all types of gels and blots. The new look range (G:BOX Chemi XRQ, G:BOX Chemi XX6 and XX9) combine a unique motorized stage (XX6 and XX9) and super-cooled camera inside a streamlined new light-tight darkroom. These features ensure G:BOX systems produce true to life, low-noise optical images rather than poor quality, digitally enhanced ones. With a G:BOX system, scientists can resolve close chemi and fluorescent bands and know they’re real, which means these systems are ideal for robust quantification of as little as femtogram quantities of DNA and proteins on multiple gel and blot types. With the option to add Red, Green, Blue and Infra Red Hi-Intensity ( HI-LED) lights that are up to 200 times brighter than standard LEDs, the new G:BOX range offers fast exposure times and produces brilliant multiplex fluorescence images. With a G:BOX Chemi system, users can detect up to five fluorescent channels sequentially (from UV to IR) on Western blots. For higher performance and resolution, researchers can use a G:BOX Chemi XX6 or XX9 for imaging close bands or spots even on complex 2D gels. At the heart of the new look G:BOX range is the unique, application driven, GeneSys software which walks users through hassle-free imaging set up. With minimal hands on time, scientists can easily design customised workflows to rapidly and reproducibly produce publication quality images of chemi, multiplex fluorescence blots, DNA and stain-free protein gels. The software includes QuickQuant, for band quantification, saving scientists time, by allowing them to quantify images of protein and DNA bands while capturing their blot or gel images at their G:BOX system. To complete the package, the new G:BOX systems come with Syngene’s exclusive three-year service and support warranty, unlimited copies of GeneTools image analysis software and free software upgrades, ensuring scientists will always have access to the latest application capabilities without any hidden extra costs. To find out more about the exciting new look G:BOX range, please click this link: hxxps://www.syngene.com/product/gbox-chemi-xx6-xx9-gel-imaging-for-fluorescence-and-chemiluminescence/ “Modern researchers want to get optimum imaging from simple gels right through to multiplex fluorescence applications, with minimal hands on time” says Dr Martin Biggs, Sales Manager at Syngene. “Our new systems perform perfectly to fit these needs, so scientists wanting hassle free imaging and results they can trust, should look at Syngene’s new G:BOX range today.”
rivaldo
01/5/2018
11:09
It is good to see ProReveal now starting to sell in Norway and Romania Possibly due to Norway looking at potential problems to come via a vCJD/BSE like diseases caused by CWD hTTp://www.hjortevilt.no/skrantesjuke-cwd/cwd-in-norway-english/ Worryingly CWD has now just been found also in Finland CWD is a prion disease like BSE was Here is the latest .... Department for Environment, Food and Rural AffairsAnimal & Plant Health Agency Veterinary & Science Policy Advice Team - International Disease Monitoring Situation Assessment ........ Update on Chronic Wasting Disease in Europe .......... 25 April 2018 Disease report In March 2016, the cervid Transmissible Spongiform Encephalopathy (TSE), or Chronic Wasting Disease (CWD) was reported in reindeer in Europe for the first time with a case in Norway. The source of infection and time and route of incursion is not known. This is an update on the surveillance results in Norway and also includes an assessment of the first case of an atypical TSE/CWD case reported in Finland. There have been no detections of CWD in Europe outside Norway and Finland to date and no cases of cervid TSEs in the UK. This report is to inform readers of the ongoing likelihood of more CWD cases in Europe and also the risks to the UK. Attention is also drawn to a forthcoming paper documenting detection of prion disease in camels in Algeria. This demonstrates the need for ongoing awareness of TSEs in other livestock species in different parts of the world. As I have said before .... the Whale in the room continues to pass through , unseen by 99% of all those in it hTTps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/703368/sa-cwd-norway-20180425.pdf
buywell3
01/5/2018
10:29
Cheers hastings, great coverage. Here's a direct link: Https://www.cambridge-news.co.uk/business/business-news/buying-building-paying-dividends-cambridge-14595865 Good extracts, particularly re Sentek: "The division, which is the UK's largest independent manufacturer of electrochemical sensors for water based applications, delivered a stronger second half performance than was previously expected which in turn was assisted by increased demand from two large OEM customers. Additionally, Sentek has taken up the opportunity to facilitate continued growth with an added extra facility to double capacity that had previously been earmarked being adjacent to its existing HQ." And acquisitions: "Creedon, while content with the progress, anticipates further additions to the group with a sizeable banking facility now in place to support that goal should they need it. There is he says, currently a strong pipeline of further potential acquisitions that fit the bill for SDI and holders or watchers of the shares will no doubt hear more on that front in due course." And ProReveal: "sales have been made overseas in both Norway and Romania which sees the total since launch of the device now standing at 76. The vast US market also remains on the agenda for future adoption and growth, although it would appear that the UK, given that looming deadline date remains the primary focus for now." "Creedon is certainly not one to raise hopes on the device, but says he will be interested to see exactly what happens come July, as this is the date that has been set by the department of health (DoH) regarding healthcare providers engaged in the management and decontamination of surgical instruments implementing their guidance on protein levels being measured directly on the surface of the instrument."
rivaldo
30/4/2018
16:19
Added some further thoughts and comment that may be of interest.https://www.cambridge-news.co.uk/business/business-news/buying-building-paying-dividends-cambridge-14595865
hastings
30/4/2018
08:44
Thanks for the update from Mello,,a great success by all accounts :-)
cheshire man
29/4/2018
08:00
Great to see Friday's "ahead of expectations" trading update. I particularly like the confident outlook comment, which promises well for the coming year: "SDI is benefitting from its acquisitions as well as from the improvements management continue to make across the whole Group. We look forward to further growth in the new financial year." Finncap seem to be playing things down prior to the prelims, so may well upgrade the target price etc after the actual results. Hopefully there'll be another earnings-enhancing acquisition along fairly soon too. I was at Mello on Thursday/Friday, and Paul Scott featured SDI quite heavily as one to watch in his Friday morning slot, so this may attract a few newbies into the stock.
rivaldo
27/4/2018
14:26
................... Time for some numbers ...................... As I have posted recently IMO SDI should hit £1 within 5 years , I said it first (I don't hide my light under any bushel/s) Last Interims Unaudited Interim Results for the six months to 31 October 2017 Scientific Digital Imaging plc, the AIM quoted group focused on the design and manufacture of scientific and technology products for use by the life science, healthcare, astronomy, consumer manufacturing and art conservation markets, is pleased to announce its unaudited interim results for the six months ended 31 October 2017. Highlights · Revenue increased by 34% to £6,552,000 (2016: £4,902,000) · Revenue growth driven by organic and acquisitions; the organic revenue growth was delivered by Sentek and Atik Cameras with the growth from acquisitions delivered by Astles Control Systems and Applied Thermal Control · Gross margin increased to 67.0% (2016: 63.6%) · Adjusted profit before tax* increased by 140% to £1,089,000 (2016: £454,000) · Profit before tax increased by 106% to £846,000 (2016: £410,000) · Basic earnings per share increased by 53% to 0.98p (2016: 0.64p) · Acquisition of Applied Thermal Control in August 2017 My post buywell3 - 30 Jan 2018 - 08:28:43 - 1059 of 1140 SDI - Global & Niche imaging portfolio for scientific & medical users - SDI SDI second half turnover over 1st half should be another 1M from ATC alone Plus whatever NHS ProReveal orders come in to meet July 2018 DoH date Plus improvements on existing divisions , say another 10% (conservative ) A decent chance to add around 2M to 2.5M in second half over 1st half earnings per share of around 1.25 to maybe 1.5p second half if current Sentek trading carries on the way it is Hence I now think following todays update(which supports the above) , that Turnover for the year should be circa £15.5M , and that earnings per share should now be circa 2.5p a share , not bad eh. But it gets better I posted buywell3 - 31 Jan 2018 - 18:42:35 - 1069 of 1140 SDI - Global & Niche imaging portfolio for scientific & medical users - SDI Let me be the first to give this share the £1 call Assuming the BOD carry on the same way buying one small cap company per year making profits and with little/no debt, in the same way they have for the last 4 to 5 years , that give X selling opportunities and a bigger spread of offerings for clients ... that FIT what SDI do A 10% increase in turnover each year looks doable Profits should be over £4M within 4 years as of now My call for SDI is 100p within 5 years Added today If my £15.5M turnover call for the full year proves correct then 10% uplift yearly equates to around £24.3M ... £4M plus profits look easily doable hTTps://en-gb.calculatestuff.com/financial/compound-interest-calculator BUT if SDI does indeed align itself to the Bioprocess Industry , then 12.5% yearly looks likely ie £27.1M turnover and £6M profits At a P/E of a measly 17:1 this would give SDI a market cap of £102M over 3 times todays Mkt Cap of 33 I think we will see another EU buyer of SDI shares within 6 months IMO The Bioprocess market is hot .... hence the new coolers that ATC have developed will sell well. ''Applied Thermal Control ATC, acquired in August 2017, is redesigning one of its chiller systems to comply with new EU regulations prohibiting the sale of equipment containing fluorinated greenhouse gas from 2022. These new chillers will work in bioprocessing systems and will be tested for use by one of the world's largest suppliers of bioprocess automation. This is a growing market which is also served by our Sentek brand. ATC is a complementary fit to the SDI Group and provides potential areas for growth as ATC can access our European network of dealers to market their products'' ''Sentek Sentek increased sales turnover by 23% in the period, driven by continuing strong sales growth of its single-use electrodes. These electrodes are used in bioprocessing and process analytics applications and Sentek is an OEM supplier to two major life science and healthcare companies. Since sales of the systems made by these companies are increasing globally to pharmaceuticals and biotech customers, sales of the electrodes continue to grow in line. Sentek has also seen growth in demand for its ion selective electrodes as a major UK competitor has ceased trading leaving Sentek as the only UK manufacturer of this type of electrode. To ensure the brand maintains quality and meets production demands, Sentek has leased an additional building to double the size of its manufacturing facility and has recruited additional production staff.'' re our new German Investors , Siemens gets a mention ''Arguably, the real star and seemingly a gem of a buy for the company has come in the shape of Sentek which produces pH conductivity sensors for water based applications. This division saw an impressive 23 per cent increase in revenues to £1.7m which was driven by strong demand from various OEM customers that includes Siemens TAP Biosystems which serves the fast growing bioprocessing segment of the Pharma and Biotech markets. ''
buywell3
27/4/2018
10:41
I posted a few months ago that foreign companies/funds were increasingly looking at UK companies due to the weakness of the £ V the Euro the £ is still around 25% discounted to what it was a couple of years back . Obviously they want companies that they see are well run, have a good growth strategy in place , one that is proven by a recent record of rising revenues, rising profits , and well managed debt. The BOD of SDI are now doing the business , they have now a proven recipe for success. An acquisition each year at an appropriate time ( adds half year in first year ) , plus an acquisition that provides the fit/s that enhance the groups growing list of already acquired companies , and an acquisition that is a good buy ie also showing turnover record of growth/profits and little or no debt. It is somewhat amazing that the BOD of SDI keep on unearthing these gems ... but they do ... and long may it continue. The latest update is much more detailed than those that have gone before Scientific Digital Imaging upgrades full-year guidance Fri, 27th April 2018 Scientific Digital Imaging said it expected its annual revenue and adjusted profit to be 'moderately' ahead of previous expectations. In addition, the company said its reported net profit was expected to benefit from a reduced tax charge, which would include increased R&D tax credits. Revenue grew significantly, reflecting both organic growth and acquisitions, it added. Margins were expected to be ahead of FY17, mainly due to the inclusion of a one-off retrospective licencing payment for the sale of imaging software. 'SDI is benefitting from its acquisitions as well as from the improvements management continue to make across the whole group,' chief executive Ken Ford said. Following the update the NOMAD has upped their guidance to around 1p under , what the latest German acquirer of 5.2% of SDI shares has been paying. At least a move in the right direction albeit still behind the curve IMO as we know SDI have another acquisition planned for 2018 Broker Forecast - finnCap issues a broker note on Scientific Digital Imaging PLC Fri, 27th April 2018 finnCap today reaffirms its corporate investment rating on Scientific Digital Imaging PLC (LON:SDI) and raised its price target to 37p (from 34p). Perhaps we will see the 4xp guidance number come after the next results ... and then another after the next acquisition. Happy days ... and I wonder if yet another EU Institutional Investor/company/fund will be the next one to take a stake in SDI. See my previous post on the '' bioprocessing market'' Most of SDI's recent acquisitions are heavily involved in the bioprocessing market February 12, 2018 A study last year by Research and Markets projected the market for bioprocessing technology to zoom from $39.3 billion in 2016 to $71.03 billion by 2021. The market for bioprocess technology is growing with the rise and development of biologics: A study last year by Research and Markets projected that market to zoom from $39.3 billion in 2016 to $71.03 billion by 2021, based on a compound annual growth rate (CAGR) of 12.4% over the five-year period This is why I did a post a few months ago which projected where SDI should be in 5 years time assuming a 10% turnover rise each year. It might be worth looking at it now.
buywell3
27/4/2018
09:33
Many positives in today's update apart from the obvious "moderately ahead of expectations" Even with the strength of the pound as you point out modform, there is also the additional benefit to profit after tax from the US tax cuts and increased R&D tax credits. There are also continuing benefits to come from the acquisitions over the past 3 years which have been bought on very good term and are very earnings enhancing. For example SDI trades on an historic PSR at 1.86 and net margin of 12.89%, below are the figures for the major acquisitions at the time of purchase. This also gives confidence in managements ability to negotiate further earning enhancing acquisitions. Sentek, PSR - 0.77 and net margins of 15.38% Astles, PSR - 2.5 and net margins of 36.4% Applied Thermal - PSR - 1.0 and net margins of 10%
interceptor2
27/4/2018
08:29
Very good even with the recent strength of £
modform
27/4/2018
08:16
Very reassuring TU :-)
cheshire man
27/4/2018
08:11
Great update. Moderately ahead of revised and upgraded forecasts and improvement in margins.
cfro
Chat Pages: 48  47  46  45  44  43  42  41  40  39  38  37  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180525 01:38:19